Scipher Medicine use a patient's unique molecular data to deliver optimal therapy, seeking to improve lives and save money through precision medicine. Their platform is intended to employ artificial intelligence to decide which drug will be most effective for each patient. Schiper is constructing a molecular map of all protein interactions to identify genomic signatures and link those to disease and predictive treatment outcomes. Scipher Medicine can predict whether a patient will respond to a targeted medicine using a simple blood sample and RNA analysis before the therapy is prescribed. Having raised a total of $117 million in three financing rounds since its inception in 2015, Scipher Medicine announced the close of a $110M round led by Cowen Inc., with participation from new investors Neuberger Berman, Hitachi Ventures, Laurion Capital Management LP, and Monashee Investment Management LLC. Existing investors Northpond Ventures, aMoon Fund, Khosla Ventures, Optum Ventures, Echo Health Ventures, and Alumni Ventures also participated. Here is the 24-slide pitch deck Scipher Medicine used to secure $110 million from leading growth & venture capital firms: Read more: vip.graphics/scipher-pitch-deck/ See the deck: bestpitchdeck.com/scipher